Numerous studies are devoted to the use of farmapram (alprazolam) in generalized anxiety disorder (GAD). GAD symptomatology is effectively reduced by farmapram therapy in an average daily dosage of 0.5-4.0 mg divided into 3-4 doses in different age groups of patients, as confirmed by numerous placebo-controlled studies. At the same time, it is established that, in comparison with other benzodiazepine tranquilizers, the use of alprazolam is accompanied by a smaller number of side effects. It is necessary to note and rather fast onset of effect, appearing already within the first week of treatment. Despite the high efficacy of alprazolam in the treatment of GID, antidepressants are currently preferred for the treatment of this pathology. However, even in this case, the role of benzodiazepines in GST treatment cannot be underestimated. Taking into account that the effect of antidepressants becomes apparent only after several weeks of therapy, the use of benzodiazepines at the beginning of treatment for anxiety and insomnia has no alternative yet. Because of the risk of drug dependence, it is recommended that farmapram (alprazolam) be used for several weeks, followed by gradual withdrawal. In cases where this period is not sufficient for the development of a sustained therapeutic effect, longer use of the drug is possible with careful dynamic monitoring.
In the study of alprazolam effectiveness in patients with GERD manifested by irritable bowel syndrome, a significant reduction both in anxiety symptoms (in 98% of patients) and gastrointestinal complaints (in 89% of patients) was observed after 4 weeks of therapy. The drug has also proven itself in the treatment of anxiety in alcohol withdrawal states.
It is mentioned repeatedly in the literature that, in addition to the anxiolytic effect itself, the drug also has an antidepressant effect, which has not been found in other tranquilizers. Its presence was discovered soon after active introduction of farmapram (alprazolam) into clinical practice and was confirmed in a number of further studies. There are indications that alprazolam is effective not only for neurotic but also for endogenous depression. Moreover, its effect is comparable to tricyclic antidepressants. Many authors indicate the preference for its use in syndromes, in the structure of which there is a combination of anxiety and depressive symptoms.
There are data indicating the effectiveness of alprazolam in the therapy of premenstrual syndrome. Successful use of alprazolam in the treatment of acute stress and obsessive-compulsive disorders has been described. The drug was prescribed either at the beginning of a course in addition to selective serotonin reuptake inhibitors (SSRIs) to relieve severe anxiety, or as monotherapy for resistance or intolerance to SSRIs. However, despite the assumptions made, alprazolam has proven ineffective in the treatment of post-traumatic stress disorder (PTSD).
There are data on the use of farmapram (alprazolam) as a corrector of extrapyramidal symptoms (especially acute dystonia and akathisia) caused by taking neuroleptics. However, in the presence of other highly effective remedies for neuroleptic syndrome, alprazolam cannot be considered as a first-line drug. The most common side effects of therapy with alprazolam are sedation and somnolence, which is explained by the interaction of the drug with GABAA-receptors and during the course of treatment, the above side effects are reduced to a great extent.